Biohaven Pharmaceutical Holding (NYSE:BHVN) has collaborated with Cove, a specialized care and access company for migraine sufferers via telemedicine services in the U.S.
The collaboration aims to further expand patients’
access to migraine treatments, like NURTEC ODT (rimegepant), an orally
disintegrating tablet for acute treatment of migraine in adults.
Existing offerings include a two-dose
complementary sample pack available with a prescription from healthcare
providers, a patient starter kit and a co-pay card.
https://seekingalpha.com/news/3558897-biohaven-teams-up-cove-for-nurtec-odt
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.